nodes	percent_of_prediction	percent_of_DWPC	metapath
Amlexanox—IL3—hematologic cancer	0.341	0.499	CbGaD
Amlexanox—FGF1—hematologic cancer	0.24	0.352	CbGaD
Amlexanox—PDE4B—hematologic cancer	0.102	0.149	CbGaD
Amlexanox—IL3—hematopoietic system—hematologic cancer	0.00725	0.122	CbGeAlD
Amlexanox—IL3—blood—hematologic cancer	0.0048	0.0811	CbGeAlD
Amlexanox—IL3—bone marrow—hematologic cancer	0.00465	0.0785	CbGeAlD
Amlexanox—S100A12—hematopoietic system—hematologic cancer	0.00339	0.0573	CbGeAlD
Amlexanox—IL3—lymph node—hematologic cancer	0.00288	0.0486	CbGeAlD
Amlexanox—S100A13—gonad—hematologic cancer	0.00262	0.0442	CbGeAlD
Amlexanox—S100A12—blood—hematologic cancer	0.00225	0.038	CbGeAlD
Amlexanox—S100A12—bone marrow—hematologic cancer	0.00218	0.0368	CbGeAlD
Amlexanox—FGF1—hematopoietic system—hematologic cancer	0.00212	0.0358	CbGeAlD
Amlexanox—S100A13—lung—hematologic cancer	0.002	0.0338	CbGeAlD
Amlexanox—S100A12—lung—hematologic cancer	0.00197	0.0333	CbGeAlD
Amlexanox—S100A13—testis—hematologic cancer	0.00188	0.0318	CbGeAlD
Amlexanox—S100A12—testis—hematologic cancer	0.00186	0.0314	CbGeAlD
Amlexanox—FGF1—blood—hematologic cancer	0.0014	0.0237	CbGeAlD
Amlexanox—S100A13—lymph node—hematologic cancer	0.00137	0.0231	CbGeAlD
Amlexanox—S100A12—lymph node—hematologic cancer	0.00135	0.0228	CbGeAlD
Amlexanox—PDE4D—lung—hematologic cancer	0.00131	0.0222	CbGeAlD
Amlexanox—PDE4D—testis—hematologic cancer	0.00124	0.021	CbGeAlD
Amlexanox—FGF1—lung—hematologic cancer	0.00123	0.0208	CbGeAlD
Amlexanox—PDE4B—hematopoietic system—hematologic cancer	0.00119	0.0202	CbGeAlD
Amlexanox—PDE4A—lung—hematologic cancer	0.00116	0.0197	CbGeAlD
Amlexanox—FGF1—testis—hematologic cancer	0.00116	0.0196	CbGeAlD
Amlexanox—S100A13—Cyclophosphamide—Mechlorethamine—hematologic cancer	0.00112	0.259	CbGdCrCtD
Amlexanox—PDE4A—testis—hematologic cancer	0.0011	0.0186	CbGeAlD
Amlexanox—S100A13—Cyclophosphamide—Ifosfamide—hematologic cancer	0.00095	0.22	CbGdCrCtD
Amlexanox—PDE4B—gonad—hematologic cancer	0.000908	0.0153	CbGeAlD
Amlexanox—PDE4D—lymph node—hematologic cancer	0.000899	0.0152	CbGeAlD
Amlexanox—FGF1—lymph node—hematologic cancer	0.000841	0.0142	CbGeAlD
Amlexanox—PDE4A—lymph node—hematologic cancer	0.000796	0.0134	CbGeAlD
Amlexanox—PDE4B—blood—hematologic cancer	0.000791	0.0134	CbGeAlD
Amlexanox—PDE4B—bone marrow—hematologic cancer	0.000766	0.0129	CbGeAlD
Amlexanox—PDE4B—lung—hematologic cancer	0.000694	0.0117	CbGeAlD
Amlexanox—PDE4B—testis—hematologic cancer	0.000655	0.0111	CbGeAlD
Amlexanox—PDE4B—lymph node—hematologic cancer	0.000475	0.00802	CbGeAlD
Amlexanox—Liver function test abnormal—Thalidomide—hematologic cancer	0.000384	0.00417	CcSEcCtD
Amlexanox—S100A13—Ponatinib—Nilotinib—hematologic cancer	0.000379	0.0877	CbGdCrCtD
Amlexanox—Stomatitis—Lenalidomide—hematologic cancer	0.000377	0.00409	CcSEcCtD
Amlexanox—Stomatitis—Hydroxyurea—hematologic cancer	0.000372	0.00404	CcSEcCtD
Amlexanox—Liver function test abnormal—Carmustine—hematologic cancer	0.000369	0.00401	CcSEcCtD
Amlexanox—Nervous system disorder—Clofarabine—hematologic cancer	0.000367	0.00398	CcSEcCtD
Amlexanox—Nervous system disorder—Pentostatin—hematologic cancer	0.000365	0.00397	CcSEcCtD
Amlexanox—Nervous system disorder—Anagrelide—hematologic cancer	0.000365	0.00397	CcSEcCtD
Amlexanox—Paraesthesia—Nelarabine—hematologic cancer	0.000359	0.0039	CcSEcCtD
Amlexanox—Stomatitis—Bortezomib—hematologic cancer	0.000347	0.00377	CcSEcCtD
Amlexanox—Headache—Vorinostat—hematologic cancer	0.000346	0.00375	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Nelarabine—hematologic cancer	0.000345	0.00375	CcSEcCtD
Amlexanox—Stomatitis—Bleomycin—hematologic cancer	0.000344	0.00374	CcSEcCtD
Amlexanox—Pain—Nelarabine—hematologic cancer	0.000342	0.00371	CcSEcCtD
Amlexanox—Stomatitis—Vinorelbine—hematologic cancer	0.000339	0.00368	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Methoxsalen—hematologic cancer	0.000337	0.00366	CcSEcCtD
Amlexanox—Paraesthesia—Clofarabine—hematologic cancer	0.000336	0.00365	CcSEcCtD
Amlexanox—Paraesthesia—Pentostatin—hematologic cancer	0.000334	0.00363	CcSEcCtD
Amlexanox—Paraesthesia—Anagrelide—hematologic cancer	0.000334	0.00363	CcSEcCtD
Amlexanox—Liver function test abnormal—Gemcitabine—hematologic cancer	0.000334	0.00363	CcSEcCtD
Amlexanox—Nausea—Vorinostat—hematologic cancer	0.000328	0.00356	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Mercaptopurine—hematologic cancer	0.000328	0.00356	CcSEcCtD
Amlexanox—Stomatitis—Thiotepa—hematologic cancer	0.000323	0.00351	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Clofarabine—hematologic cancer	0.000323	0.00351	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Anagrelide—hematologic cancer	0.000322	0.00349	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Pentostatin—hematologic cancer	0.000322	0.00349	CcSEcCtD
Amlexanox—Pain—Daunorubicin—hematologic cancer	0.00032	0.00347	CcSEcCtD
Amlexanox—Pain—Clofarabine—hematologic cancer	0.00032	0.00347	CcSEcCtD
Amlexanox—S100A13—Adenosine monophosphate—Clofarabine—hematologic cancer	0.000319	0.0739	CbGdCrCtD
Amlexanox—Pain—Anagrelide—hematologic cancer	0.000319	0.00346	CcSEcCtD
Amlexanox—Pain—Pentostatin—hematologic cancer	0.000319	0.00346	CcSEcCtD
Amlexanox—Nervous system disorder—Busulfan—hematologic cancer	0.000318	0.00345	CcSEcCtD
Amlexanox—Stomatitis—Thalidomide—hematologic cancer	0.000313	0.0034	CcSEcCtD
Amlexanox—Nervous system disorder—Bexarotene—hematologic cancer	0.000302	0.00328	CcSEcCtD
Amlexanox—Nervous system disorder—Dasatinib—hematologic cancer	0.000302	0.00328	CcSEcCtD
Amlexanox—Nervous system disorder—Fludarabine—hematologic cancer	0.000301	0.00327	CcSEcCtD
Amlexanox—Stomatitis—Carmustine—hematologic cancer	0.0003	0.00326	CcSEcCtD
Amlexanox—S100A13—Adenosine monophosphate—Nelarabine—hematologic cancer	0.0003	0.0695	CbGdCrCtD
Amlexanox—Stomatitis—Alitretinoin—hematologic cancer	0.000298	0.00323	CcSEcCtD
Amlexanox—S100A13—Vitamin A—Alitretinoin—hematologic cancer	0.000296	0.0685	CbGdCrCtD
Amlexanox—Stomatitis—Ifosfamide—hematologic cancer	0.000294	0.00319	CcSEcCtD
Amlexanox—Nausea—Lomustine—hematologic cancer	0.000294	0.00319	CcSEcCtD
Amlexanox—S100A13—Ponatinib—Imatinib—hematologic cancer	0.000287	0.0665	CbGdCrCtD
Amlexanox—Stomatitis—Vincristine—hematologic cancer	0.000287	0.00311	CcSEcCtD
Amlexanox—Paraesthesia—Procarbazine—hematologic cancer	0.000282	0.00306	CcSEcCtD
Amlexanox—Nausea—Mechlorethamine—hematologic cancer	0.000282	0.00306	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Busulfan—hematologic cancer	0.00028	0.00304	CcSEcCtD
Amlexanox—Stomatitis—Mitoxantrone—hematologic cancer	0.000279	0.00303	CcSEcCtD
Amlexanox—Stomatitis—Irinotecan—hematologic cancer	0.000279	0.00303	CcSEcCtD
Amlexanox—Nervous system disorder—Nilotinib—hematologic cancer	0.000279	0.00303	CcSEcCtD
Amlexanox—Nervous system disorder—Imatinib—hematologic cancer	0.000277	0.00301	CcSEcCtD
Amlexanox—Pain—Busulfan—hematologic cancer	0.000277	0.00301	CcSEcCtD
Amlexanox—Paraesthesia—Bexarotene—hematologic cancer	0.000277	0.003	CcSEcCtD
Amlexanox—Paraesthesia—Fludarabine—hematologic cancer	0.000276	0.00299	CcSEcCtD
Amlexanox—Nervous system disorder—Cladribine—hematologic cancer	0.000273	0.00296	CcSEcCtD
Amlexanox—Stomatitis—Gemcitabine—hematologic cancer	0.000272	0.00295	CcSEcCtD
Amlexanox—Pain—Procarbazine—hematologic cancer	0.000269	0.00292	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Bexarotene—hematologic cancer	0.000266	0.00289	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Dasatinib—hematologic cancer	0.000266	0.00289	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Fludarabine—hematologic cancer	0.000265	0.00288	CcSEcCtD
Amlexanox—Pain—Dasatinib—hematologic cancer	0.000263	0.00286	CcSEcCtD
Amlexanox—Pain—Bexarotene—hematologic cancer	0.000263	0.00286	CcSEcCtD
Amlexanox—Pain—Fludarabine—hematologic cancer	0.000263	0.00285	CcSEcCtD
Amlexanox—Paraesthesia—Nilotinib—hematologic cancer	0.000255	0.00277	CcSEcCtD
Amlexanox—Paraesthesia—Imatinib—hematologic cancer	0.000254	0.00276	CcSEcCtD
Amlexanox—Stomatitis—Cisplatin—hematologic cancer	0.000254	0.00275	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Chlorambucil—hematologic cancer	0.000251	0.00273	CcSEcCtD
Amlexanox—Headache—Nelarabine—hematologic cancer	0.00025	0.00272	CcSEcCtD
Amlexanox—Paraesthesia—Cladribine—hematologic cancer	0.00025	0.00271	CcSEcCtD
Amlexanox—Pain—Chlorambucil—hematologic cancer	0.000249	0.0027	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Nilotinib—hematologic cancer	0.000246	0.00267	CcSEcCtD
Amlexanox—Headache—Methoxsalen—hematologic cancer	0.000245	0.00266	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Imatinib—hematologic cancer	0.000244	0.00265	CcSEcCtD
Amlexanox—Pain—Nilotinib—hematologic cancer	0.000243	0.00264	CcSEcCtD
Amlexanox—Pain—Imatinib—hematologic cancer	0.000242	0.00263	CcSEcCtD
Amlexanox—Nervous system disorder—Lenalidomide—hematologic cancer	0.000242	0.00263	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Cladribine—hematologic cancer	0.00024	0.00261	CcSEcCtD
Amlexanox—Paraesthesia—Vinblastine—hematologic cancer	0.000239	0.0026	CcSEcCtD
Amlexanox—Nervous system disorder—Hydroxyurea—hematologic cancer	0.000238	0.00259	CcSEcCtD
Amlexanox—Pain—Cladribine—hematologic cancer	0.000238	0.00258	CcSEcCtD
Amlexanox—Nausea—Nelarabine—hematologic cancer	0.000237	0.00258	CcSEcCtD
Amlexanox—Headache—Clofarabine—hematologic cancer	0.000234	0.00255	CcSEcCtD
Amlexanox—Headache—Daunorubicin—hematologic cancer	0.000234	0.00255	CcSEcCtD
Amlexanox—S100A13—Adenosine monophosphate—Fludarabine—hematologic cancer	0.000234	0.0542	CbGdCrCtD
Amlexanox—Headache—Pentostatin—hematologic cancer	0.000233	0.00253	CcSEcCtD
Amlexanox—Headache—Anagrelide—hematologic cancer	0.000233	0.00253	CcSEcCtD
Amlexanox—Stomatitis—Etoposide—hematologic cancer	0.000232	0.00252	CcSEcCtD
Amlexanox—Nausea—Methoxsalen—hematologic cancer	0.000232	0.00252	CcSEcCtD
Amlexanox—Mouth ulceration—Methotrexate—hematologic cancer	0.000231	0.00251	CcSEcCtD
Amlexanox—Pain—Vinblastine—hematologic cancer	0.000228	0.00248	CcSEcCtD
Amlexanox—Paraesthesia—Melphalan—hematologic cancer	0.000228	0.00247	CcSEcCtD
Amlexanox—Nausea—Mercaptopurine—hematologic cancer	0.000225	0.00245	CcSEcCtD
Amlexanox—Headache—Idarubicin—hematologic cancer	0.000225	0.00244	CcSEcCtD
Amlexanox—Nervous system disorder—Bortezomib—hematologic cancer	0.000223	0.00242	CcSEcCtD
Amlexanox—Nausea—Clofarabine—hematologic cancer	0.000222	0.00241	CcSEcCtD
Amlexanox—Nausea—Daunorubicin—hematologic cancer	0.000222	0.00241	CcSEcCtD
Amlexanox—Paraesthesia—Lenalidomide—hematologic cancer	0.000221	0.0024	CcSEcCtD
Amlexanox—S100A13—Adenosine monophosphate—Cytarabine—hematologic cancer	0.000221	0.0512	CbGdCrCtD
Amlexanox—Nausea—Pentostatin—hematologic cancer	0.000221	0.0024	CcSEcCtD
Amlexanox—Nausea—Anagrelide—hematologic cancer	0.000221	0.0024	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Melphalan—hematologic cancer	0.000219	0.00238	CcSEcCtD
Amlexanox—Headache—Teniposide—hematologic cancer	0.000219	0.00238	CcSEcCtD
Amlexanox—Nervous system disorder—Vinorelbine—hematologic cancer	0.000217	0.00236	CcSEcCtD
Amlexanox—Pain—Melphalan—hematologic cancer	0.000217	0.00235	CcSEcCtD
Amlexanox—Mouth ulceration—Epirubicin—hematologic cancer	0.000216	0.00234	CcSEcCtD
Amlexanox—S100A13—Adenosine monophosphate—Cladribine—hematologic cancer	0.000216	0.0499	CbGdCrCtD
Amlexanox—Nausea—Idarubicin—hematologic cancer	0.000213	0.00232	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Lenalidomide—hematologic cancer	0.000213	0.00231	CcSEcCtD
Amlexanox—Pain—Lenalidomide—hematologic cancer	0.000211	0.00229	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Hydroxyurea—hematologic cancer	0.00021	0.00228	CcSEcCtD
Amlexanox—Pain—Hydroxyurea—hematologic cancer	0.000208	0.00226	CcSEcCtD
Amlexanox—Nausea—Teniposide—hematologic cancer	0.000208	0.00225	CcSEcCtD
Amlexanox—Nervous system disorder—Thiotepa—hematologic cancer	0.000208	0.00225	CcSEcCtD
Amlexanox—Paraesthesia—Bortezomib—hematologic cancer	0.000204	0.00221	CcSEcCtD
Amlexanox—Headache—Busulfan—hematologic cancer	0.000203	0.0022	CcSEcCtD
Amlexanox—Paraesthesia—Bleomycin—hematologic cancer	0.000202	0.0022	CcSEcCtD
Amlexanox—Nervous system disorder—Thalidomide—hematologic cancer	0.000201	0.00218	CcSEcCtD
Amlexanox—Mouth ulceration—Doxorubicin—hematologic cancer	0.0002	0.00217	CcSEcCtD
Amlexanox—Paraesthesia—Vinorelbine—hematologic cancer	0.000199	0.00216	CcSEcCtD
Amlexanox—Headache—Procarbazine—hematologic cancer	0.000197	0.00214	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Bortezomib—hematologic cancer	0.000196	0.00213	CcSEcCtD
Amlexanox—Pain—Bortezomib—hematologic cancer	0.000194	0.00211	CcSEcCtD
Amlexanox—Headache—Bexarotene—hematologic cancer	0.000193	0.00209	CcSEcCtD
Amlexanox—Headache—Dasatinib—hematologic cancer	0.000193	0.00209	CcSEcCtD
Amlexanox—Pain—Bleomycin—hematologic cancer	0.000193	0.00209	CcSEcCtD
Amlexanox—Headache—Fludarabine—hematologic cancer	0.000192	0.00209	CcSEcCtD
Amlexanox—Nausea—Busulfan—hematologic cancer	0.000192	0.00209	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Vinorelbine—hematologic cancer	0.000191	0.00208	CcSEcCtD
Amlexanox—Nervous system disorder—Alitretinoin—hematologic cancer	0.000191	0.00207	CcSEcCtD
Amlexanox—Paraesthesia—Thiotepa—hematologic cancer	0.00019	0.00206	CcSEcCtD
Amlexanox—Pain—Vinorelbine—hematologic cancer	0.000189	0.00206	CcSEcCtD
Amlexanox—Nervous system disorder—Ifosfamide—hematologic cancer	0.000189	0.00205	CcSEcCtD
Amlexanox—Nausea—Procarbazine—hematologic cancer	0.000187	0.00203	CcSEcCtD
Amlexanox—Nervous system disorder—Vincristine—hematologic cancer	0.000184	0.002	CcSEcCtD
Amlexanox—Paraesthesia—Thalidomide—hematologic cancer	0.000184	0.002	CcSEcCtD
Amlexanox—Nausea—Dasatinib—hematologic cancer	0.000183	0.00199	CcSEcCtD
Amlexanox—Nausea—Bexarotene—hematologic cancer	0.000183	0.00199	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Thiotepa—hematologic cancer	0.000183	0.00198	CcSEcCtD
Amlexanox—Nausea—Fludarabine—hematologic cancer	0.000182	0.00198	CcSEcCtD
Amlexanox—Pain—Thiotepa—hematologic cancer	0.000181	0.00196	CcSEcCtD
Amlexanox—Nervous system disorder—Irinotecan—hematologic cancer	0.000179	0.00195	CcSEcCtD
Amlexanox—Headache—Nilotinib—hematologic cancer	0.000178	0.00194	CcSEcCtD
Amlexanox—Headache—Imatinib—hematologic cancer	0.000177	0.00192	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Thalidomide—hematologic cancer	0.000177	0.00192	CcSEcCtD
Amlexanox—Paraesthesia—Carmustine—hematologic cancer	0.000176	0.00192	CcSEcCtD
Amlexanox—Pain—Thalidomide—hematologic cancer	0.000175	0.0019	CcSEcCtD
Amlexanox—Paraesthesia—Alitretinoin—hematologic cancer	0.000175	0.0019	CcSEcCtD
Amlexanox—Nervous system disorder—Gemcitabine—hematologic cancer	0.000175	0.0019	CcSEcCtD
Amlexanox—Headache—Cladribine—hematologic cancer	0.000174	0.00189	CcSEcCtD
Amlexanox—Nausea—Chlorambucil—hematologic cancer	0.000173	0.00188	CcSEcCtD
Amlexanox—Paraesthesia—Ifosfamide—hematologic cancer	0.000173	0.00188	CcSEcCtD
Amlexanox—Liver function test abnormal—Methotrexate—hematologic cancer	0.000171	0.00186	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Carmustine—hematologic cancer	0.00017	0.00184	CcSEcCtD
Amlexanox—Nausea—Nilotinib—hematologic cancer	0.000169	0.00184	CcSEcCtD
Amlexanox—Paraesthesia—Vincristine—hematologic cancer	0.000168	0.00183	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Alitretinoin—hematologic cancer	0.000168	0.00183	CcSEcCtD
Amlexanox—Pain—Carmustine—hematologic cancer	0.000168	0.00183	CcSEcCtD
Amlexanox—Nausea—Imatinib—hematologic cancer	0.000168	0.00182	CcSEcCtD
Amlexanox—Headache—Vinblastine—hematologic cancer	0.000167	0.00181	CcSEcCtD
Amlexanox—Pain—Alitretinoin—hematologic cancer	0.000167	0.00181	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Ifosfamide—hematologic cancer	0.000166	0.0018	CcSEcCtD
Amlexanox—Nausea—Cladribine—hematologic cancer	0.000165	0.00179	CcSEcCtD
Amlexanox—Pain—Ifosfamide—hematologic cancer	0.000165	0.00179	CcSEcCtD
Amlexanox—Paraesthesia—Irinotecan—hematologic cancer	0.000164	0.00178	CcSEcCtD
Amlexanox—Paraesthesia—Mitoxantrone—hematologic cancer	0.000164	0.00178	CcSEcCtD
Amlexanox—Nervous system disorder—Cisplatin—hematologic cancer	0.000163	0.00177	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Vincristine—hematologic cancer	0.000162	0.00176	CcSEcCtD
Amlexanox—Pain—Vincristine—hematologic cancer	0.00016	0.00174	CcSEcCtD
Amlexanox—Liver function test abnormal—Epirubicin—hematologic cancer	0.00016	0.00174	CcSEcCtD
Amlexanox—Paraesthesia—Gemcitabine—hematologic cancer	0.00016	0.00174	CcSEcCtD
Amlexanox—Nausea—Vinblastine—hematologic cancer	0.000158	0.00172	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Irinotecan—hematologic cancer	0.000158	0.00171	CcSEcCtD
Amlexanox—Pain—Mitoxantrone—hematologic cancer	0.000156	0.0017	CcSEcCtD
Amlexanox—Pain—Irinotecan—hematologic cancer	0.000156	0.0017	CcSEcCtD
Amlexanox—Headache—Lenalidomide—hematologic cancer	0.000154	0.00168	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Gemcitabine—hematologic cancer	0.000154	0.00167	CcSEcCtD
Amlexanox—Headache—Hydroxyurea—hematologic cancer	0.000152	0.00165	CcSEcCtD
Amlexanox—Pain—Gemcitabine—hematologic cancer	0.000152	0.00165	CcSEcCtD
Amlexanox—Nausea—Melphalan—hematologic cancer	0.000151	0.00164	CcSEcCtD
Amlexanox—Paraesthesia—Cisplatin—hematologic cancer	0.000149	0.00162	CcSEcCtD
Amlexanox—Liver function test abnormal—Doxorubicin—hematologic cancer	0.000148	0.00161	CcSEcCtD
Amlexanox—Nausea—Lenalidomide—hematologic cancer	0.000146	0.00159	CcSEcCtD
Amlexanox—Nausea—Hydroxyurea—hematologic cancer	0.000144	0.00157	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Cisplatin—hematologic cancer	0.000143	0.00156	CcSEcCtD
Amlexanox—Headache—Bortezomib—hematologic cancer	0.000142	0.00154	CcSEcCtD
Amlexanox—Pain—Cisplatin—hematologic cancer	0.000142	0.00154	CcSEcCtD
Amlexanox—Stomatitis—Methotrexate—hematologic cancer	0.000139	0.00151	CcSEcCtD
Amlexanox—Headache—Vinorelbine—hematologic cancer	0.000139	0.00151	CcSEcCtD
Amlexanox—Paraesthesia—Etoposide—hematologic cancer	0.000136	0.00148	CcSEcCtD
Amlexanox—Nausea—Bortezomib—hematologic cancer	0.000135	0.00146	CcSEcCtD
Amlexanox—Paraesthesia—Prednisolone—hematologic cancer	0.000135	0.00146	CcSEcCtD
Amlexanox—Nausea—Bleomycin—hematologic cancer	0.000134	0.00145	CcSEcCtD
Amlexanox—Headache—Thiotepa—hematologic cancer	0.000133	0.00144	CcSEcCtD
Amlexanox—Nausea—Vinorelbine—hematologic cancer	0.000132	0.00143	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Etoposide—hematologic cancer	0.000131	0.00142	CcSEcCtD
Amlexanox—Stomatitis—Epirubicin—hematologic cancer	0.00013	0.00141	CcSEcCtD
Amlexanox—Pain—Etoposide—hematologic cancer	0.00013	0.00141	CcSEcCtD
Amlexanox—Headache—Thalidomide—hematologic cancer	0.000128	0.00139	CcSEcCtD
Amlexanox—Pain—Prednisolone—hematologic cancer	0.000128	0.00139	CcSEcCtD
Amlexanox—Nausea—Thiotepa—hematologic cancer	0.000126	0.00136	CcSEcCtD
Amlexanox—Paraesthesia—Triamcinolone—hematologic cancer	0.000124	0.00134	CcSEcCtD
Amlexanox—Headache—Carmustine—hematologic cancer	0.000123	0.00134	CcSEcCtD
Amlexanox—Nervous system disorder—Betamethasone—hematologic cancer	0.000123	0.00133	CcSEcCtD
Amlexanox—Nervous system disorder—Dexamethasone—hematologic cancer	0.000123	0.00133	CcSEcCtD
Amlexanox—Headache—Alitretinoin—hematologic cancer	0.000122	0.00132	CcSEcCtD
Amlexanox—Nausea—Thalidomide—hematologic cancer	0.000122	0.00132	CcSEcCtD
Amlexanox—Stomatitis—Doxorubicin—hematologic cancer	0.00012	0.00131	CcSEcCtD
Amlexanox—Pain—Triamcinolone—hematologic cancer	0.000118	0.00128	CcSEcCtD
Amlexanox—Headache—Vincristine—hematologic cancer	0.000118	0.00128	CcSEcCtD
Amlexanox—Nausea—Carmustine—hematologic cancer	0.000117	0.00127	CcSEcCtD
Amlexanox—Nausea—Alitretinoin—hematologic cancer	0.000116	0.00126	CcSEcCtD
Amlexanox—Headache—Mitoxantrone—hematologic cancer	0.000114	0.00124	CcSEcCtD
Amlexanox—Headache—Irinotecan—hematologic cancer	0.000114	0.00124	CcSEcCtD
Amlexanox—Nausea—Ifosfamide—hematologic cancer	0.000114	0.00124	CcSEcCtD
Amlexanox—Paraesthesia—Betamethasone—hematologic cancer	0.000112	0.00122	CcSEcCtD
Amlexanox—Paraesthesia—Dexamethasone—hematologic cancer	0.000112	0.00122	CcSEcCtD
Amlexanox—Headache—Gemcitabine—hematologic cancer	0.000112	0.00121	CcSEcCtD
Amlexanox—Nausea—Vincristine—hematologic cancer	0.000111	0.00121	CcSEcCtD
Amlexanox—Nausea—Mitoxantrone—hematologic cancer	0.000109	0.00118	CcSEcCtD
Amlexanox—Nausea—Irinotecan—hematologic cancer	0.000109	0.00118	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Dexamethasone—hematologic cancer	0.000108	0.00117	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Betamethasone—hematologic cancer	0.000108	0.00117	CcSEcCtD
Amlexanox—Pain—Betamethasone—hematologic cancer	0.000107	0.00116	CcSEcCtD
Amlexanox—Pain—Dexamethasone—hematologic cancer	0.000107	0.00116	CcSEcCtD
Amlexanox—Nervous system disorder—Prednisone—hematologic cancer	0.000107	0.00116	CcSEcCtD
Amlexanox—Nausea—Gemcitabine—hematologic cancer	0.000106	0.00115	CcSEcCtD
Amlexanox—Nausea—Cisplatin—hematologic cancer	9.85e-05	0.00107	CcSEcCtD
Amlexanox—Paraesthesia—Prednisone—hematologic cancer	9.78e-05	0.00106	CcSEcCtD
Amlexanox—Headache—Etoposide—hematologic cancer	9.52e-05	0.00103	CcSEcCtD
Amlexanox—Headache—Prednisolone—hematologic cancer	9.39e-05	0.00102	CcSEcCtD
Amlexanox—Nausea—Etoposide—hematologic cancer	9.03e-05	0.00098	CcSEcCtD
Amlexanox—Nervous system disorder—Methotrexate—hematologic cancer	8.93e-05	0.000969	CcSEcCtD
Amlexanox—Nausea—Prednisolone—hematologic cancer	8.9e-05	0.000967	CcSEcCtD
Amlexanox—Headache—Triamcinolone—hematologic cancer	8.64e-05	0.000938	CcSEcCtD
Amlexanox—Nervous system disorder—Epirubicin—hematologic cancer	8.36e-05	0.000907	CcSEcCtD
Amlexanox—Nausea—Triamcinolone—hematologic cancer	8.19e-05	0.000889	CcSEcCtD
Amlexanox—Paraesthesia—Methotrexate—hematologic cancer	8.17e-05	0.000888	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Methotrexate—hematologic cancer	7.86e-05	0.000853	CcSEcCtD
Amlexanox—Headache—Dexamethasone—hematologic cancer	7.84e-05	0.000851	CcSEcCtD
Amlexanox—Headache—Betamethasone—hematologic cancer	7.84e-05	0.000851	CcSEcCtD
Amlexanox—Pain—Methotrexate—hematologic cancer	7.79e-05	0.000845	CcSEcCtD
Amlexanox—Nervous system disorder—Doxorubicin—hematologic cancer	7.73e-05	0.000839	CcSEcCtD
Amlexanox—Paraesthesia—Epirubicin—hematologic cancer	7.65e-05	0.000831	CcSEcCtD
Amlexanox—Nausea—Betamethasone—hematologic cancer	7.43e-05	0.000807	CcSEcCtD
Amlexanox—Nausea—Dexamethasone—hematologic cancer	7.43e-05	0.000807	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Epirubicin—hematologic cancer	7.36e-05	0.000799	CcSEcCtD
Amlexanox—Pain—Epirubicin—hematologic cancer	7.29e-05	0.000791	CcSEcCtD
Amlexanox—Paraesthesia—Doxorubicin—hematologic cancer	7.08e-05	0.000769	CcSEcCtD
Amlexanox—Headache—Prednisone—hematologic cancer	6.82e-05	0.000741	CcSEcCtD
Amlexanox—Gastrointestinal disorder—Doxorubicin—hematologic cancer	6.81e-05	0.000739	CcSEcCtD
Amlexanox—Pain—Doxorubicin—hematologic cancer	6.74e-05	0.000732	CcSEcCtD
Amlexanox—Nausea—Prednisone—hematologic cancer	6.47e-05	0.000703	CcSEcCtD
Amlexanox—Headache—Methotrexate—hematologic cancer	5.7e-05	0.000619	CcSEcCtD
Amlexanox—Nausea—Methotrexate—hematologic cancer	5.41e-05	0.000587	CcSEcCtD
Amlexanox—Headache—Epirubicin—hematologic cancer	5.34e-05	0.00058	CcSEcCtD
Amlexanox—Nausea—Epirubicin—hematologic cancer	5.06e-05	0.00055	CcSEcCtD
Amlexanox—Headache—Doxorubicin—hematologic cancer	4.94e-05	0.000536	CcSEcCtD
Amlexanox—Nausea—Doxorubicin—hematologic cancer	4.68e-05	0.000508	CcSEcCtD
Amlexanox—PDE4B—Signaling Pathways—NFKBIA—hematologic cancer	3.68e-06	2.29e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—BAD—hematologic cancer	3.68e-06	2.29e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—PIK3CA—hematologic cancer	3.68e-06	2.29e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CREB1—hematologic cancer	3.67e-06	2.28e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—HRAS—hematologic cancer	3.66e-06	2.28e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MDM2—hematologic cancer	3.66e-06	2.28e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—IL6—hematologic cancer	3.65e-06	2.27e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NOTCH1—hematologic cancer	3.65e-06	2.27e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MTOR—hematologic cancer	3.64e-06	2.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CB—hematologic cancer	3.64e-06	2.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL1B—hematologic cancer	3.63e-06	2.26e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CD4—hematologic cancer	3.63e-06	2.26e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—BRAF—hematologic cancer	3.62e-06	2.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FGFR3—hematologic cancer	3.62e-06	2.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL2—hematologic cancer	3.62e-06	2.25e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCL2—hematologic cancer	3.59e-06	2.23e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAPK14—hematologic cancer	3.58e-06	2.23e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAP2K1—hematologic cancer	3.58e-06	2.23e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6R—hematologic cancer	3.58e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CREBBP—hematologic cancer	3.57e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CD80—hematologic cancer	3.57e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CG—hematologic cancer	3.57e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KIT—hematologic cancer	3.57e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—NRAS—hematologic cancer	3.57e-06	2.22e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CB—hematologic cancer	3.56e-06	2.21e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MTOR—hematologic cancer	3.56e-06	2.21e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CD—hematologic cancer	3.56e-06	2.21e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—PIK3CA—hematologic cancer	3.52e-06	2.19e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—JUN—hematologic cancer	3.52e-06	2.19e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—ESR1—hematologic cancer	3.52e-06	2.19e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PTPN11—hematologic cancer	3.5e-06	2.18e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—KRAS—hematologic cancer	3.48e-06	2.17e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FN1—hematologic cancer	3.47e-06	2.16e-05	CbGpPWpGaD
Amlexanox—S100A12—Immune System—AKT1—hematologic cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NFKBIA—hematologic cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—BAD—hematologic cancer	3.43e-06	2.13e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—MAPK3—hematologic cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1B—hematologic cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—CDKN1A—hematologic cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAP2K1—hematologic cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—FGF2—hematologic cancer	3.41e-06	2.12e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PTEN—hematologic cancer	3.4e-06	2.12e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—HRAS—hematologic cancer	3.4e-06	2.11e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NOTCH1—hematologic cancer	3.4e-06	2.11e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CREB1—hematologic cancer	3.39e-06	2.11e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—PIK3CA—hematologic cancer	3.39e-06	2.11e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CD—hematologic cancer	3.39e-06	2.11e-05	CbGpPWpGaD
Amlexanox—FGF1—Innate Immune System—AKT1—hematologic cancer	3.37e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3R1—hematologic cancer	3.36e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—PIK3CA—hematologic cancer	3.36e-06	2.09e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—BRAF—hematologic cancer	3.35e-06	2.08e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1B—hematologic cancer	3.34e-06	2.08e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MAPK8—hematologic cancer	3.33e-06	2.07e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CD80—hematologic cancer	3.33e-06	2.07e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CG—hematologic cancer	3.32e-06	2.07e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KIT—hematologic cancer	3.32e-06	2.07e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCL2—hematologic cancer	3.32e-06	2.06e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—KRAS—hematologic cancer	3.32e-06	2.06e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6R—hematologic cancer	3.31e-06	2.06e-05	CbGpPWpGaD
Amlexanox—PDE4C—GPCR downstream signaling—AKT1—hematologic cancer	3.31e-06	2.06e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CREBBP—hematologic cancer	3.31e-06	2.05e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—TP53—hematologic cancer	3.28e-06	2.04e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CASP3—hematologic cancer	3.28e-06	2.04e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL2—hematologic cancer	3.27e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—JAK2—hematologic cancer	3.27e-06	2.03e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PTPN11—hematologic cancer	3.27e-06	2.03e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—IL6—hematologic cancer	3.26e-06	2.02e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—EP300—hematologic cancer	3.25e-06	2.02e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—FGF2—hematologic cancer	3.24e-06	2.02e-05	CbGpPWpGaD
Amlexanox—FGF1—Adaptive Immune System—AKT1—hematologic cancer	3.23e-06	2.01e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—PIK3CA—hematologic cancer	3.2e-06	1.99e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3R1—hematologic cancer	3.2e-06	1.99e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CCND1—hematologic cancer	3.19e-06	1.98e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MDM2—hematologic cancer	3.19e-06	1.98e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—JUN—hematologic cancer	3.18e-06	1.98e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CREB1—hematologic cancer	3.16e-06	1.97e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—SRC—hematologic cancer	3.16e-06	1.96e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAP2K1—hematologic cancer	3.16e-06	1.96e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—CDKN1A—hematologic cancer	3.15e-06	1.96e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PTEN—hematologic cancer	3.14e-06	1.95e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—HRAS—hematologic cancer	3.14e-06	1.95e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CD—hematologic cancer	3.13e-06	1.95e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—BRAF—hematologic cancer	3.12e-06	1.94e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—JAK2—hematologic cancer	3.11e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—PIK3CA—hematologic cancer	3.1e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MTOR—hematologic cancer	3.1e-06	1.93e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CB—hematologic cancer	3.1e-06	1.93e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCL2—hematologic cancer	3.1e-06	1.92e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6R—hematologic cancer	3.09e-06	1.92e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—CDKN1A—hematologic cancer	3.09e-06	1.92e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CREBBP—hematologic cancer	3.08e-06	1.92e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PTEN—hematologic cancer	3.08e-06	1.91e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—KRAS—hematologic cancer	3.07e-06	1.91e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—PIK3CA—hematologic cancer	3.05e-06	1.89e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—STAT3—hematologic cancer	3.04e-06	1.89e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—NRAS—hematologic cancer	3.04e-06	1.89e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MDM2—hematologic cancer	3.03e-06	1.89e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MAPK8—hematologic cancer	3.01e-06	1.87e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling by GPCR—AKT1—hematologic cancer	3e-06	1.87e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—IL6—hematologic cancer	3e-06	1.87e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—FGF2—hematologic cancer	3e-06	1.86e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—EP300—hematologic cancer	3e-06	1.86e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—HRAS—hematologic cancer	2.96e-06	1.84e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3R1—hematologic cancer	2.96e-06	1.84e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MTOR—hematologic cancer	2.95e-06	1.83e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CB—hematologic cancer	2.95e-06	1.83e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAP2K1—hematologic cancer	2.94e-06	1.83e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—EP300—hematologic cancer	2.94e-06	1.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CD—hematologic cancer	2.92e-06	1.82e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—SRC—hematologic cancer	2.92e-06	1.81e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1B—hematologic cancer	2.91e-06	1.81e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—MAPK3—hematologic cancer	2.91e-06	1.81e-05	CbGpPWpGaD
Amlexanox—PDE4D—GPCR downstream signaling—AKT1—hematologic cancer	2.88e-06	1.79e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—JAK2—hematologic cancer	2.88e-06	1.79e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—SRC—hematologic cancer	2.86e-06	1.77e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CASP3—hematologic cancer	2.85e-06	1.77e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL2—hematologic cancer	2.85e-06	1.77e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—IL6—hematologic cancer	2.83e-06	1.76e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—PIK3CA—hematologic cancer	2.82e-06	1.75e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—HRAS—hematologic cancer	2.82e-06	1.75e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—STAT3—hematologic cancer	2.81e-06	1.75e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MDM2—hematologic cancer	2.81e-06	1.74e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—NRAS—hematologic cancer	2.8e-06	1.74e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—FGF2—hematologic cancer	2.8e-06	1.74e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—VEGFA—hematologic cancer	2.78e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CCND1—hematologic cancer	2.78e-06	1.73e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—JUN—hematologic cancer	2.77e-06	1.72e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1B—hematologic cancer	2.77e-06	1.72e-05	CbGpPWpGaD
Amlexanox—IL3—Signaling Pathways—AKT1—hematologic cancer	2.77e-06	1.72e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3R1—hematologic cancer	2.76e-06	1.71e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—STAT3—hematologic cancer	2.75e-06	1.71e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—NRAS—hematologic cancer	2.75e-06	1.71e-05	CbGpPWpGaD
Amlexanox—PDE4A—GPCR downstream signaling—AKT1—hematologic cancer	2.74e-06	1.7e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CB—hematologic cancer	2.73e-06	1.7e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MTOR—hematologic cancer	2.73e-06	1.7e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CASP3—hematologic cancer	2.72e-06	1.69e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL2—hematologic cancer	2.71e-06	1.69e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—IL6—hematologic cancer	2.7e-06	1.68e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—CDKN1A—hematologic cancer	2.69e-06	1.67e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MAPK3—hematologic cancer	2.69e-06	1.67e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—JAK2—hematologic cancer	2.68e-06	1.67e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PTEN—hematologic cancer	2.68e-06	1.67e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CCND1—hematologic cancer	2.64e-06	1.64e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—JUN—hematologic cancer	2.64e-06	1.64e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MAPK3—hematologic cancer	2.63e-06	1.63e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAPK8—hematologic cancer	2.62e-06	1.63e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MDM2—hematologic cancer	2.62e-06	1.63e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling by GPCR—AKT1—hematologic cancer	2.61e-06	1.63e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—KRAS—hematologic cancer	2.61e-06	1.62e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—MYC—hematologic cancer	2.61e-06	1.62e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—HRAS—hematologic cancer	2.61e-06	1.62e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—TGFB1—hematologic cancer	2.61e-06	1.62e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1B—hematologic cancer	2.56e-06	1.59e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—MYC—hematologic cancer	2.56e-06	1.59e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—CDKN1A—hematologic cancer	2.56e-06	1.59e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—EP300—hematologic cancer	2.56e-06	1.59e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TGFB1—hematologic cancer	2.55e-06	1.59e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PTEN—hematologic cancer	2.55e-06	1.59e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CB—hematologic cancer	2.55e-06	1.58e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MTOR—hematologic cancer	2.55e-06	1.58e-05	CbGpPWpGaD
Amlexanox—PDE4B—GPCR downstream signaling—AKT1—hematologic cancer	2.54e-06	1.58e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CASP3—hematologic cancer	2.51e-06	1.56e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL2—hematologic cancer	2.51e-06	1.56e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—IL6—hematologic cancer	2.5e-06	1.55e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAPK8—hematologic cancer	2.5e-06	1.55e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling by GPCR—AKT1—hematologic cancer	2.49e-06	1.55e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—SRC—hematologic cancer	2.49e-06	1.54e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CCND1—hematologic cancer	2.45e-06	1.52e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—JUN—hematologic cancer	2.44e-06	1.52e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—EP300—hematologic cancer	2.43e-06	1.51e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—VEGFA—hematologic cancer	2.42e-06	1.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—KRAS—hematologic cancer	2.41e-06	1.5e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—PIK3CA—hematologic cancer	2.4e-06	1.49e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—STAT3—hematologic cancer	2.4e-06	1.49e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—NRAS—hematologic cancer	2.39e-06	1.49e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1B—hematologic cancer	2.39e-06	1.49e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—CDKN1A—hematologic cancer	2.37e-06	1.47e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—SRC—hematologic cancer	2.37e-06	1.47e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—KRAS—hematologic cancer	2.36e-06	1.47e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PTEN—hematologic cancer	2.36e-06	1.47e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CASP3—hematologic cancer	2.34e-06	1.46e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL2—hematologic cancer	2.34e-06	1.45e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAPK8—hematologic cancer	2.31e-06	1.44e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—VEGFA—hematologic cancer	2.3e-06	1.43e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling by GPCR—AKT1—hematologic cancer	2.3e-06	1.43e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MAPK3—hematologic cancer	2.29e-06	1.42e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—STAT3—hematologic cancer	2.28e-06	1.42e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CCND1—hematologic cancer	2.28e-06	1.42e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—NRAS—hematologic cancer	2.28e-06	1.41e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—JUN—hematologic cancer	2.28e-06	1.41e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—EP300—hematologic cancer	2.25e-06	1.4e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—MYC—hematologic cancer	2.23e-06	1.38e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TGFB1—hematologic cancer	2.22e-06	1.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—HRAS—hematologic cancer	2.22e-06	1.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—PIK3CA—hematologic cancer	2.22e-06	1.38e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—CDKN1A—hematologic cancer	2.21e-06	1.37e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PTEN—hematologic cancer	2.2e-06	1.37e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—SRC—hematologic cancer	2.19e-06	1.36e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MAPK3—hematologic cancer	2.18e-06	1.35e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—PIK3CA—hematologic cancer	2.17e-06	1.35e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAPK8—hematologic cancer	2.15e-06	1.34e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—VEGFA—hematologic cancer	2.13e-06	1.33e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—IL6—hematologic cancer	2.13e-06	1.32e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—MYC—hematologic cancer	2.12e-06	1.32e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TGFB1—hematologic cancer	2.12e-06	1.31e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—STAT3—hematologic cancer	2.11e-06	1.31e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—NRAS—hematologic cancer	2.11e-06	1.31e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—TP53—hematologic cancer	2.1e-06	1.31e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—EP300—hematologic cancer	2.1e-06	1.3e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—KRAS—hematologic cancer	2.06e-06	1.28e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—HRAS—hematologic cancer	2.05e-06	1.27e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—SRC—hematologic cancer	2.04e-06	1.27e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MAPK3—hematologic cancer	2.02e-06	1.25e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—HRAS—hematologic cancer	2.01e-06	1.25e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—VEGFA—hematologic cancer	1.99e-06	1.24e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—STAT3—hematologic cancer	1.97e-06	1.22e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—NRAS—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—IL6—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—FGF1—Immune System—AKT1—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—MYC—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—KRAS—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TGFB1—hematologic cancer	1.96e-06	1.22e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—IL6—hematologic cancer	1.92e-06	1.2e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—PIK3CA—hematologic cancer	1.89e-06	1.18e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MAPK3—hematologic cancer	1.88e-06	1.17e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—TP53—hematologic cancer	1.83e-06	1.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—MYC—hematologic cancer	1.83e-06	1.14e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TGFB1—hematologic cancer	1.82e-06	1.13e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—KRAS—hematologic cancer	1.81e-06	1.13e-05	CbGpPWpGaD
Amlexanox—FGF1—Disease—AKT1—hematologic cancer	1.81e-06	1.13e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—PIK3CA—hematologic cancer	1.8e-06	1.12e-05	CbGpPWpGaD
Amlexanox—PDE4C—Signaling Pathways—AKT1—hematologic cancer	1.77e-06	1.1e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—HRAS—hematologic cancer	1.75e-06	1.09e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—TP53—hematologic cancer	1.74e-06	1.08e-05	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—KRAS—hematologic cancer	1.69e-06	1.05e-05	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—IL6—hematologic cancer	1.67e-06	1.04e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—PIK3CA—hematologic cancer	1.67e-06	1.03e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—HRAS—hematologic cancer	1.67e-06	1.03e-05	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—TP53—hematologic cancer	1.61e-06	1e-05	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—IL6—hematologic cancer	1.59e-06	9.9e-06	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—PIK3CA—hematologic cancer	1.55e-06	9.65e-06	CbGpPWpGaD
Amlexanox—PDE4D—Signaling Pathways—AKT1—hematologic cancer	1.54e-06	9.6e-06	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—HRAS—hematologic cancer	1.54e-06	9.58e-06	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—TP53—hematologic cancer	1.5e-06	9.34e-06	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—IL6—hematologic cancer	1.47e-06	9.16e-06	CbGpPWpGaD
Amlexanox—PDE4A—Signaling Pathways—AKT1—hematologic cancer	1.47e-06	9.14e-06	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—HRAS—hematologic cancer	1.44e-06	8.93e-06	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—IL6—hematologic cancer	1.38e-06	8.55e-06	CbGpPWpGaD
Amlexanox—PDE4B—Signaling Pathways—AKT1—hematologic cancer	1.36e-06	8.45e-06	CbGpPWpGaD
Amlexanox—FGF1—Signaling Pathways—AKT1—hematologic cancer	1.27e-06	7.88e-06	CbGpPWpGaD
